Clinical case - Assessment of treatment response efficiency

Assessment of Treatment

Who we are

Professor Juhani Knuuti
Director

Adj. Prof. Marko Seppänen
Diagnostic Service Manager

 

Turku PET Centre
Turku, Finland

As a Finnish National Research Institute, Turku PET Centre led by Professor J. Knuuti, promotes the use of PET in the medical research field. The Centre was founded in 1974 by the University of Turku, Åbo Akademi University and the Turku University Hospital. The Centre integrates top scientific expertise with excellent facilities and equipments. Fruitful interaction and collaboration between basic scientists and clinical investigators is a long-standing tradition.

The latest imaging technology is available, some unique in Europe. The Centre provides several tracers for routine and research clinical imaging in Oncology, Neurology and Cardiology, using the Europe's first 64 slices PET/CT system. With its excellent cyclotron and radiochemistry laboratories, Turku PET Centre develops and produces the latest PET tracers for clinical imaging.

Patient History

Male - 38 years old – 176cm - 77kg

In March 2007: operated for a rectum carcinoma, histopathologically confirmed as adenoma carcinoma gradus II.

Postoperative follow-up showed a raising CEA.

Patient refers to 18F-FDG scan for recurrence assessment.

Acquisition

Scanner: GE Discovery VCT

PET acquisition: Whole-body 18F-FDG acquisition

  • 3D acquisition reconstructed with VUE Point HD & analysed with PETVCAR™
  • Acquisition time: 12 min
  • Post-injection time: 50 min
  • Dose: June 2008: 382 MBq & August 2008: 368 MBq

CT acquisition:

  • Rotation speed: 0.8 second
  • FOV: 70 cm
  • Pitch: 1.375 mm/rot
  • Slice thickness: 3.75 mm
  • Smart mA, NI: 25, kVp: 140, mA: 80

Findings

 

Assessment of Treatment

    June 2008                                                   August 2008 Coronal
    Coronal whole-body                                 whole-body PET image
    PET image confirming                               a significant partial
    liver recurrence                                         response to therapy

June 2008:

The 18F-FDG PET scan reveals a disease recurrence.
A highly hypermetabolic lesion is found in the caudate (segment 1)
of liver. The patient is treated with chemotherapy.

August 2008:

The patient is scanned for treatment response evaluation.
The PET scan shows a significant partial response.
A resection of the liver can now be considered by the surgeon.

Conclusion

Early treatment to response evaluation with integrated PET/CT may also be a valuable approach in patients with solid tumors and its clinical role may rise in the future when optimizing treatment protocols of these patients.

PET VCAR™ is a strong new tool for follow up studies, enabling a more effective interpretation of patient data.